Online ISSN: 2250-1177
Interested in submitting to this journal? We recommend that you review the About the Journal page for the journal's section policies, as well as the Author Guidelines. Authors need to Register with the journal prior to submitting or, if already registered, can simply log in and begin the five-step process.
The journal allows authors to deposit all versions of their paper (submitted, accepted, and published versions) in an institutional or other repository of their choice.
OCLC/OAIster (OAIster: Catalog of open access resources | OCLC)
- Aim and Scope
- Peer Review Process
- Publication Frequency
- Open Access Policy
- Publication Ethics and Malpractice Statement
- Screening for plagiarism
- Article Submission Charges: Submission of an article is Free
- Article Processing Charges and Waiver Policy: Detail is given below;
Journal of Drug Delivery and Therapeutics is an Open Access journal. Publishing an article in this Journal requires Article Processing Charges that will be billed to the submitting author following the acceptance of an article for publication. Apart from these Article Process Charges, there are no submission charges, page charges, or color charges. The fees to be paid following the acceptance of an article are indicated below:
INR 2000 +18%GST per article for Indian Authors
USD 55/article for Authors from Low-Income Countries.
USD 65/article for Authors from Low-Middle Income Countries.
USD 75/article for Authors from Upper-Middle-Income Countries
USD 120/article for Authors from High-Income Countries. (No other hidden charges)
Waiver Policy as per World Bank Country Classification
We provide a waiver of Article Processing Charges to authors based on country classification by World Bank and Processing charges decided as per countries classified World Bank Country Classification
We can also waive 100% in some special condition depend on if there is no funding and author not able to charge any fees. In order to apply for a waiver, please request one before submitting your manuscript by sending an email to email@example.com
For more details about the list of countries as per the classification of World Bank' go to below Link;
POLICY STATEMENT – CONFLICT OF INTEREST
All Authors publishing in Journal of Drug Delivery and Therapeutics must declare all financial disclosures and conflicts of interest in the article file of manuscripts submitted for publication. For more information on Conflict of Interest, see the guidelines from the ICMJE.
POLICY STATEMENT – INFORMED CONSENT
All human studies submitted for publication in Journal of Drug Delivery and Therapeutics require informed consent and ethics committee approval. If waiver of consent was granted by the ethics committee in the case of retrospective studies not impacting on patient confidentiality or patient rights, this must be clearly stated in the cover letter and manuscript.
POLICY STATEMENT – HUMAN AND ANIMAL RIGHTS
Any investigations involving humans and animals should be approved by the Institutional Review Board and Animal Care Committee, respectively, of the institution where the study took place. Journal of Drug Delivery and Therapeutics will not consider any studies involving humans or animals without the appropriate approval. If no formal ethics committee is available, the authors should indicate whether the procedures were compliant with the Helsinki Declaration as revised in 2008. Informed consent should be obtained, unless waived by the Institutional Review Board, from patients who participated in clinical investigations. Human subjects should not be identifiable, such that patients' names, initials, hospital numbers, dates of birth, or other protected healthcare information should not be disclosed. If experiments involve animals, the research should be based on national or institutional guidelines for animal care and use. Original articles submitted to Journal of Drug Delivery and Therapeutics that address any investigation involving humans and animals should include a description about whether
the study was conducted under an approval by the Institutional Review Board (with or without patient informed consent) and animal care committee, respectively, of the institution where the study was conducted.